Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark N Levine

Showing results (31-40 of 111) with videos related to

Pageof 12
Sort By:
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 3, 2014
Kit for the preparation of <sup>111</sup>In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)Karen Lam, Deborah A Scollard, Conrad Chan, et al.
BMC Medical Research Methodology|March 23, 2013
Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer studySameer Parpia, Lehana Thabane, Jim A Julian, et al.
Radiology|August 5, 2025
<sup>18</sup>F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc AnalysisUr Metser, Seyed Ali Mirshahvalad, Ian S Dayes, et al.
Nuclear Medicine and Biology|December 3, 2014
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumabKaren Lam, Conrad Chan, Susan J Done, et al.
Thrombosis and Haemostasis|June 22, 2005
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patientsMichael J Kovacs, Mark N Levine, Michael Keeney, et al.
Journal of Oncology Practice|December 12, 2013
Cost effectiveness of a survivorship care plan for breast cancer survivorsDoug Coyle, Eva Grunfeld, Kathryn Coyle, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 29, 2013
Uptake of an innovation in surgery: observations from the cluster-randomized Quality Initiative in Rectal Cancer trialMarko Simunovic, Angela Coates, Andrew Smith, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 29, 2013
Patterns of use and outcomes for radiation therapy in the Quality Initiative in Rectal Cancer (QIRC) trialValerie Francescutti, Angela Coates, Lehana Thabane, et al.
Clinical Lung Cancer|April 17, 2026
Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized TrialYanchen Wang, Elysia K Donovan, Mark N Levine, et al.
BMJ Open|October 26, 2014
Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancerSameer Parpia, Jim A Julian, Lehana Thabane, et al.
Pageof 12

Showing results (31-40 of 111) with videos related to

Sort By:
Pageof 12
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 3, 2014
Kit for the preparation of <sup>111</sup>In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)Karen Lam, Deborah A Scollard, Conrad Chan, et al.
BMC Medical Research Methodology|March 23, 2013
Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer studySameer Parpia, Lehana Thabane, Jim A Julian, et al.
Radiology|August 5, 2025
<sup>18</sup>F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc AnalysisUr Metser, Seyed Ali Mirshahvalad, Ian S Dayes, et al.
Nuclear Medicine and Biology|December 3, 2014
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumabKaren Lam, Conrad Chan, Susan J Done, et al.
Thrombosis and Haemostasis|June 22, 2005
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patientsMichael J Kovacs, Mark N Levine, Michael Keeney, et al.
Journal of Oncology Practice|December 12, 2013
Cost effectiveness of a survivorship care plan for breast cancer survivorsDoug Coyle, Eva Grunfeld, Kathryn Coyle, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 29, 2013
Uptake of an innovation in surgery: observations from the cluster-randomized Quality Initiative in Rectal Cancer trialMarko Simunovic, Angela Coates, Andrew Smith, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 29, 2013
Patterns of use and outcomes for radiation therapy in the Quality Initiative in Rectal Cancer (QIRC) trialValerie Francescutti, Angela Coates, Lehana Thabane, et al.
Clinical Lung Cancer|April 17, 2026
Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized TrialYanchen Wang, Elysia K Donovan, Mark N Levine, et al.
BMJ Open|October 26, 2014
Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancerSameer Parpia, Jim A Julian, Lehana Thabane, et al.
Pageof 12